Acute and chronic pancreatitis: epidemiology and clinical aspects
Spanier, B.W.M.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Incidence and mortality of acute and chronic pancreatitis in the Netherlands: a nationwide record-linked cohort study for the years 1995-2005

B.W. Marcel Spanier¹
Marco J. Bruno²
Marcel G.W. Dijkgraaf³

¹ Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem
² Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam
³ Clinical Research Unit, Academic Medical Center, Amsterdam
Abstract

**BACKGROUND** Over the last decades, the incidence of acute pancreatitis and chronic pancreatitis seems to have increased in the Western countries, while the overall population mortality has remained stable.

**AIM** To analyze the trends in incidence and mortality rates of acute and chronic pancreatitis in the Netherlands and for international standard populations.

**METHODS** Nationwide cohort identified through record linkage of hospital admission data for acute and chronic pancreatitis, accumulated from three distinct nationwide Dutch registries for the years 1995-2005. The European and WHO standard populations were used.

**RESULTS** The incidence of acute pancreatitis per 100,000 persons per year increased between 2000 and 2005 from 13.2 (95% CI: 12.6-13.8) to 14.7 (95% CI: 14.1-15.3). The incidence rate of acute pancreatitis for males increased from 13.8 (95% CI: 12.9-14.7) to 15.2 (95% CI: 14.3-16.1), for females from 12.7 (95% CI: 11.9-13.5) to 14.2 (95% CI: 13.4-15.1). Irregular patterns over time emerged for chronic pancreatitis. The overall mean incidence per 100,000 persons per year was 1.77, for males 2.16, and for females 1.4. Mortality for acute pancreatitis fluctuated during 1995-2005 between 6.9 to 11.7 per million persons per year and was almost similar for males and females. Concerning chronic pancreatitis, the mortality for males fluctuated between 1.1 (95% CI: 0.6-2.3) and 4.0 (95% CI: 2.8-5.8), for females between 0.7 (95% CI: 0.3-1.6) and 2.0 (95% CI: 1.2-3.2). Incidence and mortality rates of AP and CP increased markedly by age. Standardized rates were lowest for the WHO standard population.

**CONCLUSIONS** The incidence of acute pancreatitis steadily increased while the incidence of chronic pancreatitis fluctuated between 2000 and 2005. On average, mortality for both acute and chronic pancreatitis remained fairly stable. It is to be expected that patient burden and health care costs will increase because of an ageing Dutch population.
Introduction

Over the last decades, the incidence and number of hospital admissions of both acute and chronic pancreatitis have consistently increased in the Western countries. Increasing alcohol intake, more gallstone-related pancreatitis, increased pancreatic enzyme testing and improvements of diagnostic tests and interventional techniques have all been suggested as possible explanations.

The disease spectrum of acute pancreatitis (ap) ranges from mild and self-limiting (~85%) to a life-threatening illness resulting in significant morbidity and mortality. At onset, ap regularly results in hospitalization. Generally, in the Western countries the case fatality proportion of ap decreased over time, but the overall population mortality did not change.

Chronic pancreatitis (cp) is characterized by ongoing or recurrent episodes of abdominal pain accompanied by progressive pancreatic exocrine and endocrine insufficiency. Hospitalization is required in case of an exacerbation to control pain (e.g. opioid medication, endoscopic duct drainage, pancreaticojejunostomy and/or resection) and for the treatment of complications such as pseudocysts. The overall survival for cp patients is reduced compared with the standard population. Most notably because of the impact of non-pancreatic effects of excess alcohol consumption and/or smoking, independent of cp itself.

Epidemiological studies from the Netherlands for ap are scarce and this is even more the case for cp. Eland et al. reported the latest incidence rates and mortality of ap from 1985 to 1995, both based on hospital discharge data. Recently, we reported about the trend in hospital admissions in the Netherlands for ap and cp. For both groups, the hospital admissions have increased substantially from 1992 to 2004.

In this study we report the incidence rates of ap and cp for the period 2000-2005 and mortality rates of ap and cp for the period 1995-2005 following linkage of three distinct nation-wide Dutch registries. Additionally, data on incidence and mortality rates over time are reported for Dutch and international standard populations.

Methods

Case finding

Cases of ap and cp were identified by linkage of three distinct nation-wide Dutch registries: the hospital discharge register (HDR), the population register (PR), and the death certificate register (DCR). The HDR contains discharge data from academic and general hospitals in the Netherlands (www.dutchhospitaldata.nl). Since 1992 almost all (>97%)...
Dutch hospitals are linked to the HDR with 99% coverage of all hospital admissions. For each hospital discharge the date of admission, date of discharge, type of admission, and diagnoses at discharge (primary and secondary) are recorded along with anonymous characteristics of discharged persons like; sex, date of birth, postal code of the living address, and country of origin. Hospital discharge diagnoses in the HDR are coded according to the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9CM). We retrospectively retrieved all hospital admissions (>1 day of hospital stay) for the period 1 January 1995-31 December 2005 from the HDR with acute (code 577.0) or chronic (code 577.1) pancreatitis as the primary discharge diagnoses.

A single patient with multiple admissions will have several records in the HDR. Because of its anonymous nature however, only partially identifiable information is provided at the record level. For the accurate count of pancreatitis cases, it is necessary to identify different admissions, potentially in different hospitals, by the same patient. To identify these unique cases in the HDR the records were linked to the PR which is maintained by Statistics Netherlands of the Dutch Ministry of Economy Affairs. Statistics Netherlands collects demographic and economical data about the Dutch population. The PR contains continuously updated demographic data on all citizens residing in the Netherlands like name, date of birth, sex, nationality, living address, dates of immigration and/or emigration, and date of death.

HDR records can be linked to the PR by a combination of three identifiers: sex, date of birth, and (the numeric part of) the postal code at the time of admission. Linkage fails if several citizens are of the same sex, are born on the same date, and live in the same postal code area at the time at least one of them is admitted (‘administrative siblings’). Also, linkage fails if any key data are lacking in the HDR or in the PR. The linkage procedure is performed by Statistics Netherlands and the result is provided to researchers after adding a unique, encrypted personal identifier to linked records of the HDR.

Statistics Netherlands enables the unique linkage of about 86% of all yearly hospital admissions to the PR, suggesting that counts at the person level should be multiplied by 100/86 to derive national estimates. However, the probability of unique linkage is not equal across subgroups in the general population and over time. For instance, persons in high-density population areas, persons born in countries with inaccurate birth dates, and moving persons have a lower probability of unique linkage. To compensate for linkage failure, stratum-specific multipliers were calculated for sex, 5-yearly age cohorts, and country of origin (see Appendix). While doing so, we took into account that our aim was to estimate the incidence rather than the prevalence of pancreatitis.

From case finding to incident cases
We defined an incident case during any specific year as a person with an admission for AP or CP during that year which is not preceded by another admission of the same person with the same discharge diagnosis during at least five years prior to the specified year. To identify incident cases, it is mandatory that all admissions during the observation
period have been identified for each person. Hence, a person known in the PR should be always uniquely identifiable during the observation period 1995-2005 based on the linkage keys sex, age, and the postal code. This always unique subpopulation of the PR may include persons born and/or deceased during the observation period, but excludes:
- persons who have been an administrative sibling any time during 1995-2005, the not always uniquely identifiable ones
- immi rating or emi grating persons, because data on admissions abroad are lacking

**Incidence rates and standardized incidence rates**
Sex- and age-specific incidence rates for the years 2000-2005 were defined as the yearly number of new pancreatitis cases per 100,000 members of the Dutch reference population alive during the year, excluding immigrated or emigrated citizens and after adjustment for stratum-specific linkage failure between the HDR and the PR. The yearly incidence rates were recalculated with reference to the age and sex distribution of the Dutch reference population in 2000 as well as with reference to the age distribution (assuming evenly distributed male and females) of the European and World Health Organization (WHO) standard populations.

**Mortality rates and standardized mortality rates**
Deaths associated with acute and CP were identified by linkage of the PR and the Death Certificate Register (DCR) which is also maintained by Statistics Netherlands. General practitioners and hospitals are obliged to complete a death certificate for each deceased person, and notify the primary and up to three secondary causes of death. Causes of death are coded according to the International Classification of Diseases coding system with acute and chronic pancreatic related death coded as 577.0 and 577.1 respectively for the year 1995 (ICD-9CM) or K850 and K860/K861 respectively for the years 1996 and later (ICD-10CM). The register is nearly complete (99.7%) with regard to persons deceased in the Netherlands, meaning that deaths after emigration are lacking. Primary causes of death are always notified, whereas secondary causes of death however can be missing and incomplete to an unknown extent. Therefore, only the primary causes of death are analyzed. The mortality rate is expressed per 1,000,000 general population members excluding the ones that emigrated any time between 1995 and 2005. Again, yearly mortality rates were recalculated with reference to the age and sex distribution of the Dutch reference population in 2000 as well as with reference to the age distribution (assuming evenly distributed males and females) of the European and WHO standard populations.

**Additional statistics**
We assumed the AP and CP incidence and mortality rates to follow Poisson distributions when calculating 95% confidence intervals. The Statistical Package for the Social Sciences (SPSS) versions 14.0 and 18.0 (SPSS, Chicago, IL) were used for statistical analysis.
Results

In 1995-2005 18,819,221 citizens were known in the population register with 49.75% being male. Slightly under 10.4 per cent immigrated or emigrated, leaving 16,866,819 patients in the Dutch reference population for the incidence estimates, 12,163,581 of whom were always uniquely identifiable during 1995-2005. Hence, the average multiplier for the incidence estimates amounted to 1387 (see also the Appendix for the stratum-specific multipliers).

Incidence rates acute pancreatitis

The overall incidence rate of AP per 100,000 persons per year increased during the 2000-2005 period from 13.2 (95% CI: 12.6-13.8) in 2000 to 14.7 (95% CI: 14.1-15.3) in 2005. The incidence rate for males rose from 13.8 (95% CI: 12.9-14.7) to 15.2 (95% CI: 14.3-16.1), for females from 12.7 (95% CI: 11.9-13.5) to 14.2 (95% CI: 13.4-15.1), reflecting yearly increases of 1.6% and 1.9% respectively [Figure 1a upper left].

Incidence rates per 100,000 persons per year ranged from below 1 in the younger age groups (< age 15) to as high as 50.7 in 2005 for the patients of 85 years and above. Figure 1b [upper right] shows the incidence rates after regrouping patients into four major age groups (<25, 25-49, 50-74, and >74). The incidence rate in the 50-74 age group was highest in 2004 (26.1; 95% CI: 24.6-27.7); in the eldest age group the incidence rate was increased in 2005 (46.5; 95% CI: 42.5-50.9) compared to the preceding years.

The mean yearly incidence rates of AP per 100,000 persons per year by 5-yearly age groups and by sex peaked at the ages of 80-84 for both, males (55.4; 95% CI: 42.8-71.6) and females (41.9; 95% CI: 33.8-52.0). The mean yearly incidence rate was higher for females (7.1; 95% CI: 4.7-10.7) than males (3.4; 95% CI: 1.9-6.0) for persons in their early twenties. However, between the ages of 44 and 84, the opposite was observed with 30-63% higher mean yearly incidence rates for males than for females.

Figures 1c [lower left; males] and 1d [lower right; females] show the original as well as the Dutch 2000, the European, and the WHO standardized incidence rates of AP per 100,000 persons per year. Both figures show lowest incidence rates for the WHO standard population (range males: 10.4-11.6; range females: 8.6-10.1), followed by the European standard population (range males: 12.5-13.9; range females: 10.0-11.7), and the Dutch standard population (range males: 13.8-15.3; range females: 12.1-14.0). The figures show that the discrepancy between the original incidence rate and the standardized rates increases over time for males, indicating a small effect of an ageing Dutch population.

Incidence rates chronic pancreatitis

The overall incidence rate of CP per 100,000 persons per year during the 2000-2005 period averaged 1.77, fluctuating between 1.52 (95% CI: 1.32-1.74) in 2001 and 1.98 (95% CI: 1.76-2.22) in 2004. Figure 2a [upper left] shows the incidence rates of male and female CP cases. The incidence rates for males averaged 2.16, 50% higher than the in-
The incidence rates for females (mean of 1.4). The incidence rates for males fluctuated over time with lower rates in the years 2001 and 2003 (both 1.9; 95% CI: 1.6-2.3) compared with the year 2000 (2.5; 95% CI: 2.1-2.9). Among females, the incidence rates during the years 2003 (1.5; 95% CI: 1.3-1.8) and 2004 (1.6; 95% CI: 1.4-2.0) were higher than during the year 2001 (1.2; 95% CI: 0.9-1.5).

Incidence rates per 100,000 persons per year ranged from below 0.5 in the younger age groups (< age 20) to as high as 5.2 (95% CI: 3.5-7.8) in 2005 for the patients between 75 and 79 years of age. Figure 2b (upper right) shows the incidence rates after regrouping patients into four major age groups (<25, 25-49, 50-74, and >74). While the incidence rate fluctuated in the 50-74 age group between 3.8 (95% CI: 3.2-4.5) in 2000 and 2.9
In 2001 and 2005, the incidence rate in the age group of 75 and older increased steadily by 75%, from 2.5 (95% CI: 1.7-3.7) in 2000 to 4.4 (95% CI: 3.2-5.8) in 2005.

The mean yearly incidence rates of CP per 100,000 persons per year for males between 65 and 74 years (65-69: 6.2, 95% CI: 3.9-9.8; 70-74: 5.1, 95% CI: 3.0-8.9) more than doubled the rates for females (65-69: 2.3, 95% CI: 1.2-4.7; 70-74: 2.4, 95% CI: 1.2-5.0).

Figures 2c [lower left; males] and 2d [lower right; females] show the original as well as the Dutch 2000, the European, and the WHO standardized incidence rates of CP per 100,000 persons per year. The incidence rates for the WHO standard population ranged from 1.4 to 1.9 for males and from 0.8 to 1.2 for females. For the European standard...
population, the ranges were 1.7-2.3 and 1.0-1.3 for males and females respectively. The ranges for the Dutch standard population in 2000 (range males: 1.9-2.5; range females: 1.2-1.6) were nearly identical to the non-standardized data.

**Mortality rates acute pancreatitis**

Between 1995 and 2005 1,524,492 persons died in the Netherlands. In 2,264 cases AP was notified as a cause of death. Of these, 65.6% or 1,484 cases (0.97 pro mille of all deceased persons) died with AP as the primary cause of death, including 764 males and 720 females.

**Figure 3a** (upper left) shows the male and female mortality rates of AP per million persons per year for 1995-2005. The mortality rates fluctuated between 6.9 to 11.7 per million persons per year and were similar for males and females except for the years 1997 and 1999 when more males than females died (1997: 11.7, 95% CI: 9.4-14.5 versus 7.26, 95% CI: 5.56-9.48); 1999: 10.3, 95% CI: 8.2-12.9 versus 7.3, 95% CI: 5.61-9.51).

**Figure 3b** (upper right) shows the mortality rates per million persons per year after regrouping patients into four major age groups (<25, 25-49, 50-74, and >74). The mortality rate for patients younger than 50 years of age stayed below 3.6 (95% CI: 2.3-5.6) per million and for the 50-74 age group below 18.6 (95% CI: 14.8-23.5) per million, whereas the mortality rate more than tripled up to 85.3 (95% CI: 69.1-105.4) per million for the oldest age group.

**Figures 3c** (lower left; males) and **3d** (lower right; females) show the original as well as the Dutch 2000, the European, and the WHO standardized mortality rates of acute pancreatitis per million persons per year. An ageing effect for males is present with in 1995 a 6.1% higher and in 2005 a 7.1% lower Dutch standardized rate compared to the original rate. On average, the mortality rates for the European and Dutch standard populations are 31.6%, respectively 36.8% higher than the WHO standard. Although the overall pattern is irregular, a gradual decline over time in mortality rates for males can be noted.

Among the females a smaller ageing effects emerges with in 1995 a 4% higher and in 2005 a 3.4% lower Dutch standardized rate compared to the non-standardized rate. On average, the mortality rates for the European and WHO standard populations are 52.7%, respectively 96.8% below the Dutch standard.

**Mortality rates chronic pancreatitis**

Between 1995 and 2005 745 patients died in the Netherlands with CP notified as a cause of death. Of these, 43.9% or 327 cases (0.21 pro mille of all deceased Dutch patients in the same period) died with CP as the primary cause of death, including 223 males and 104 females.

**Figure 4a** (upper left) shows the male and female mortality rates of CP per million persons per year for 1995-2005. The mortality rates for males fluctuated between 1.1
(95% CI: 0.6-2.3) in 1997 and 4.0 (95% CI: 2.8-5.8) in 2003, for females between 0.7 (95% CI: 0.3-1.6) in 1995 and 2.0 (95% CI: 1.2-3.2) in 2000. Except for 1997, 2000, 2002 and 2005 the male mortality rate exceeded the female mortality rate.

**Figure 4b** [upper right] shows the mortality rates per million persons per year after regrouping patients into four major age groups (<25, 25-49, 50-74, and >74). The mortality rate for patients younger than 50 years of age stayed below 2.3 (95% CI: 1.3-4.0) per million and for the 50-74 age group below 4.5 (95% CI: 2.9-7.1) per million, whereas for the oldest age group the mortality rate went up to as high as 14.7 (95% CI: 8.7-24.9) per million persons per year.


Figures 4c [lower left; males] and 4d [lower right; females] show the original as well as the Dutch 2000, the European, and the WHO standardized mortality rates of cp per million persons per year for 1995-2005. Again, an ageing effect for males is present with in 1995 a 9.7% higher and in 2005 a 7.1% lower Dutch standardized rate compared to the original rate. On average, the European and WHO standardized rates are 5.9% and 32.4% lower than the Dutch rate. No clear ageing effect is observed for females. On average, the European and WHO standardized rates are 42% and 83.5% lower than the Dutch rate.
Discussion

We performed a nationwide record-linked study to analyze the time trends of the incidence and mortality rates of AP and of CP in the Netherlands. We show that between 2000-2005 the incidence of AP per 100,000 persons per year increased over time for both, males (from 13.8 to 15.2) and females (from 12.7 to 14.2). Relatively stable patterns over time emerged for the incidence rate of AP per 100,000 persons per year by different age groups. The steady increase of the incidence of AP over time corresponds to the results of a former retrospective study performed in the Netherlands between 1985-1995.2 However, the similar growth pattern in our study was observed at a lower level. Eland et al. observed incidence rates for the year 1995 of 17.0 males and 14.8 females per 100,000 person-years. If we take for granted that no decrease in incidence rates took place during the unobserved years 1996-1999, then several decisions concerning study design may have contributed to the difference in incidence rate level. Eland and colleagues retrieved primary as well as secondary discharge diagnoses from the HDR, whereas we only included AP as a primary discharge diagnosis in order to reduce the risk of misclassification of cases. For example, a patient admitted with a pneumonia may have AP be notified as a secondary discharge diagnosis, whereas AP was the primary discharge diagnosis during a prior admission in the past. Further, we excluded single-day admissions for AP. This seems reasonable, because patients with a first attack of AP usually get admitted for several days.2,10 Moreover, by identifying unique cases following the linkage of two nationwide registries, double counting of cases is a circumvented issue in our study. Last and least (because of its negligible contribution), the denominator in the incidence rate by Eland et al. (person-years) slightly increases the estimates compared with our calculations based on persons alive during the year. Considering these reasons for differences in level despite a similar growth pattern, the former reported incidence rates in the Netherlands may be somewhat overestimated.

Other recent population-based studies in Western countries too report increasing incidence rates of AP.3,4,7,8,13,29,32 The studies - although somewhat heterogeneous by design - indicate that the reported incidence rates of AP in the Netherlands are low and even far lower compared to reported rates from several Scandinavian countries and the United States of America.16 The observed differences in incidence rates between these geographical locations is not clearly understood and presumably reflects differences in risk factor prevalence. We observed that the incidence rates of AP increased considerably with age. This is in accordance with observations elsewhere.2,4,8,30

The incidence rates of CP in the Netherlands have now been reported for the first time. In contrast to AP, irregular patterns over time emerged for the incidence rates of CP per 100,000 persons per year for males (mean: 2.16) and females (mean: 1.4). The incidence rate increased with age, with a top in 2005 at 4.4 in the age group of 75 or older. Recent large scale epidemiological studies reporting the time trends of incidence of CP
are strikingly scarce.\textsuperscript{15, 16} The latest reported incidence rates of \textit{cp} vary between 5.9 and 7.9 per 100,000 persons.\textsuperscript{5, 32, 33} In comparison to those studies, our observed incidence rates of \textit{cp} are somewhat lower. This may in part be explained by our study limitations (see below). In accordance to other studies, we show that \textit{cp} is predominantly a disease of males.\textsuperscript{6, 11, 12, 15, 16, 32} The average incidence rate for males is 50\% higher than for females. This is even more pronounced in the older age groups.

The mortality rate for \textit{ap} per million persons per year fluctuated between 6.9 to 11.7 during the 1995-2005 period. Others too reported fairly stable overall annual population mortality rates.\textsuperscript{2, 12, 13} The mortality rate increased rapidly for patients of 50 years of age and above, which too is in accordance with observation elsewhere.\textsuperscript{2, 4, 13, 30} Advanced age may be an independent risk factor for severe \textit{ap}.\textsuperscript{34} Mortality rates were almost similar for males and females.

Concerning \textit{cp}, the mortality rate per million persons per year for both males and females fluctuated within a stable bandwidth. Tinto et al. also reported that between 1979 and 1999 the age-standardized mortality rate broadly remained unchanged in England. Merely, the mortality rate for males exceeded the female rate. The mortality rate for persons of 75 years of age and older increased most promptly. Generally, the survival rate for patients with \textit{cp} is poor.\textsuperscript{15, 16, 35, 36} \textit{cp} patients tend to die of other causes such as smoking related cancers, cardiovascular disease and alcoholic liver cirrhosis.

Both incidence and mortality rates over time are reported for Dutch and international standard populations. On average, the reported rates are the lowest for the WHO standard population, followed by the European and the Dutch standard populations, which clearly reflects their different age distributions. In addition, an ageing effect was observed during the study period, particularly for male incidence rates. The ageing of the Dutch population will most likely continue for another decade, for which reason an increase in patient burden and a rise in health care costs can be anticipated.

Our study has several potential limitations. We defined an incident case during any specific year as a person with an admission that was not preceded by another admission of the same person with the same discharge diagnosis during at least five years prior to the specified year. So, an admitted, incident case in 2000 had no previous admission during 1995-1999 (five years). Further, an admitted, incident case in 2002 had no previous admission in 1995-2001 (seven years). It would have been a contradiction to allow a person to be classified as an incident case in 2002, if he had already been admitted once before in 1996 for the same reason. This analytical approach however may have led to a downward pressure on the incidence rates in later years (near 2005) compared to the earlier years (near 2000). Hence, growth patterns may be slightly underestimated.

In addition, we considered the whole observation period 1995-2005 at once, instead of six ‘moving’ time frames (1995-2000, 1996-2001, ..., 2000-2005). The longer the observation period is, the smaller is the always uniquely identifiable subpopulation. Consequently, the stratum-specific adjustment parameters are higher and time inde-
dependent. This simplification was done to limit the computational efforts considerably. It comes with a small loss of accuracy for the incidence estimates in distinct calendar years. For the interpretation of incidence trends over time however, that loss of accuracy can be neglected.

Another limitation is that we did not identify incident CP cases among the persons already identified as incident AP cases. Presumably, this resulted in only a minimal underestimation of the incidence rate of CP. A recent study showed that CP developed in alcoholic AP cases with a cumulative incidence of just 13% in 10 years.37 Only, in patients with a recurrent alcoholic AP, the incidence of CP at 2 years after initial relapse was 38%. Unfortunately, we do not have sufficient data about the aetiology of AP and CP in our study population.

Another issue concerns the reliability of the reported incidence rates which depends heavily on the HDR as a reliable source for hospital discharge data concerning AP and CP. Eland et al. performed, as a part of a retrospective study in which incidence rates of AP in the Netherlands were assessed, a restricted validation analysis.2 They concluded that the overreporting due to miscoding and the underreporting due to non-coding were comparable and that observed incidence rates seem to reflect true rates. Previously, we retrospectively analyzed the reliability of hospital discharge data of in total 483 admissions for both AP and CP collected in the HDR. We observed a substantial miscoding and non-coding of discharge diagnoses of AP and CP on the level of individual hospital admissions, ultimately leading to a limited underestimation at group level of the total number of AP and CP diagnoses of 15.8% and 6% respectively.38

Furthermore, there is a potential underestimation of the incidence rates due to non-referral of AP and CP patients. For the present study, we retrieved the AP and CP hospital admissions (>1 day of hospital stay) from the HDR. Underestimation due to non-referral is probably limited for AP, because in the Netherlands almost all AP patients are admitted to a hospital for more than one day.22 Whether or not this also holds for CP patients in the Netherlands is unknown. Generally, some CP patients, especially in the early stage of the disease, are only treated in an outpatient clinic setting and treated in a single-day hospital admission. So, by excluding the single-day admissions in our study, the underestimation will be of greater importance for CP compared to the AP. Historical volume data from the forerunner of the HDR (the earlier mentioned NISHC) on the use of hospital resources by CP patients suggest that approximately 6% of all admissions are single-day admissions. Considering that individual CP patients frequently need multiple single-day admissions, once under such treatment, it is likely that at the person count level, the degree of underestimation is even less than 6%.

In conclusion, we observed an increase in the incidence rate of AP and a fluctuating incidence rate of CP between 2000 and 2005 in the Netherlands. On average, the mortality rate for both AP and CP remained fairly stable between 1995-2005. Both incidence and mortality rates increase markedly by age and are lower for international standard
populations. Therefore, in light of the continuing ageing of the Dutch population, patient burden and health care costs will most probably increase.
Appendix

Stratum-specific multipliers* for pancreatitis incidence estimates derived from the Dutch hospital discharge registry

<table>
<thead>
<tr>
<th>Age cohort</th>
<th>Male</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Female</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Netherlands</td>
<td>Non-Western</td>
<td>Western</td>
<td></td>
<td></td>
<td></td>
<td>Netherlands</td>
<td>Non-Western</td>
<td>Western</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-4</td>
<td>1.22</td>
<td>1.33</td>
<td>1.25</td>
<td></td>
<td></td>
<td></td>
<td>1.21</td>
<td>1.31</td>
<td>1.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-9</td>
<td>1.34</td>
<td>1.62</td>
<td>1.39</td>
<td></td>
<td></td>
<td></td>
<td>1.32</td>
<td>1.59</td>
<td>1.36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-14</td>
<td>1.28</td>
<td>1.57</td>
<td>1.32</td>
<td></td>
<td></td>
<td></td>
<td>1.26</td>
<td>1.56</td>
<td>1.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-19</td>
<td>1.31</td>
<td>1.92</td>
<td>1.41</td>
<td></td>
<td></td>
<td></td>
<td>1.38</td>
<td>2.05</td>
<td>1.51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-24</td>
<td>1.71</td>
<td>2.92</td>
<td>2.03</td>
<td></td>
<td></td>
<td></td>
<td>2.03</td>
<td>3.05</td>
<td>2.38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-29</td>
<td>1.92</td>
<td>3.02</td>
<td>2.18</td>
<td></td>
<td></td>
<td></td>
<td>1.89</td>
<td>2.77</td>
<td>2.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-34</td>
<td>1.76</td>
<td>2.84</td>
<td>2.01</td>
<td></td>
<td></td>
<td></td>
<td>1.66</td>
<td>2.37</td>
<td>1.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35-39</td>
<td>1.57</td>
<td>2.64</td>
<td>1.74</td>
<td></td>
<td></td>
<td></td>
<td>1.49</td>
<td>2.06</td>
<td>1.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-44</td>
<td>1.43</td>
<td>2.33</td>
<td>1.50</td>
<td></td>
<td></td>
<td></td>
<td>1.37</td>
<td>1.85</td>
<td>1.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-49</td>
<td>1.34</td>
<td>2.08</td>
<td>1.38</td>
<td></td>
<td></td>
<td></td>
<td>1.30</td>
<td>1.76</td>
<td>1.34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50-54</td>
<td>1.30</td>
<td>1.83</td>
<td>1.34</td>
<td></td>
<td></td>
<td></td>
<td>1.28</td>
<td>1.63</td>
<td>1.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-59</td>
<td>1.25</td>
<td>1.77</td>
<td>1.26</td>
<td></td>
<td></td>
<td></td>
<td>1.24</td>
<td>1.63</td>
<td>1.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60-64</td>
<td>1.19</td>
<td>1.67</td>
<td>1.22</td>
<td></td>
<td></td>
<td></td>
<td>1.18</td>
<td>1.48</td>
<td>1.21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-69</td>
<td>1.16</td>
<td>1.64</td>
<td>1.20</td>
<td></td>
<td></td>
<td></td>
<td>1.17</td>
<td>1.43</td>
<td>1.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70-74</td>
<td>1.15</td>
<td>1.42</td>
<td>1.18</td>
<td></td>
<td></td>
<td></td>
<td>1.17</td>
<td>1.37</td>
<td>1.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-79</td>
<td>1.14</td>
<td>1.26</td>
<td>1.16</td>
<td></td>
<td></td>
<td></td>
<td>1.20</td>
<td>1.32</td>
<td>1.23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80-84</td>
<td>1.11</td>
<td>1.17</td>
<td>1.12</td>
<td></td>
<td></td>
<td></td>
<td>1.22</td>
<td>1.28</td>
<td>1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 85</td>
<td>1.05</td>
<td>1.07</td>
<td>1.06</td>
<td></td>
<td></td>
<td></td>
<td>1.13</td>
<td>1.18</td>
<td>1.13</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Stratum-specific multipliers compensate for linkage failure of the Hospital Discharge Register with the Population Register. For each stratum the multiplier was calculated by dividing the total number of citizens in the Dutch Population Registry throughout the 1995-2005 observation period by the number of persons that were always uniquely identifiable in the same period based on sex, age and the postal code. Persons who emigrated or immigrated during the observation period were excluded from these calculations. The strata (sex, 5-year age cohorts, country of origin) and their levels were chosen such that zero numbers of always uniquely identifiable pancreatitis cases were kept to the minimum. Compensation for linkage failure will be less successful, if a stratum has no always uniquely identifiable pancreatitis case.²⁶
References


